I85PREP
⌘ K
CIMC study materials
CIMC study resources

CIMC practice questions

One question at a time. Build your CIMC understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Clinical Trial Leadership and Team Management

A clinical trial team is being assembled for a Phase II oncology study. Which role is primarily accountable for the medical oversight of trial participants and for safety decisions during the study?

  1. The regulatory affairs specialist
  2. The principal investigator Correct answer.
  3. The clinical research associate
  4. The data manager

Explanation

The principal investigator holds delegated responsibility for the conduct of the trial at the site, including medical oversight of participants and safety decision-making. Other roles support monitoring, data handling, or regulatory submissions but do not carry this clinical accountability.

Question 2Clinical Trial Leadership and Team Management

During a trial, a team member repeatedly misses deadlines for entering safety data. Which action best reflects effective performance management by the study lead?

  1. Document the issue and hold a private conversation to identify causes and agree on corrective steps Correct answer.
  2. Reassign all the member's tasks to other staff without discussion
  3. Escalate directly to the ethics committee
  4. Wait until the next scheduled audit to raise the concern

Explanation

Effective performance management starts with timely, documented, private feedback and a joint plan for correction. This preserves accountability while diagnosing root causes such as workload, training gaps, or unclear expectations.

Question 3Clinical Trial Leadership and Team Management

Which document typically defines the specific responsibilities delegated by the investigator to individual site team members?

  1. The investigator's brochure
  2. The delegation of authority log Correct answer.
  3. The informed consent form
  4. The statistical analysis plan

Explanation

The delegation of authority log records which trial tasks each team member is authorized and trained to perform. It supports accountability and is reviewed during monitoring.

Question 4Clinical Trial Leadership and Team Management

A study lead wants to build mutual trust within a newly formed cross-functional team. Which approach is most consistent with established team-development practice?

  1. Rotating team membership frequently to increase flexibility
  2. Withholding project risks until they are fully resolved
  3. Setting clear goals and roles while encouraging open two-way communication Correct answer.
  4. Limiting interactions to formal written correspondence

Explanation

Trust develops when goals and roles are clear and communication is open and bidirectional. Transparency about risks and regular interaction further strengthen cohesion and psychological safety.

Question 5Clinical Trial Leadership and Team Management

Which statement best describes the purpose of a team charter in a clinical trial setting?

  1. It defines the team's mission, scope, roles, and operating norms Correct answer.
  2. It serves as the formal contract with the sponsor
  3. It documents individual participant adverse events
  4. It replaces the protocol as the governing document for the study

Explanation

A team charter aligns members around purpose, boundaries, responsibilities, and ways of working. It complements, rather than replaces, governing documents such as the protocol and contracts.

Question 6Clinical Trial Leadership and Team Management

A clinical trial manager is planning resource allocation for a study with unpredictable enrollment. Which approach best supports staffing flexibility?

  1. Cross-training staff and using flexible resourcing arrangements Correct answer.
  2. Assigning all tasks to a single coordinator
  3. Hiring permanent staff sized to peak enrollment
  4. Deferring staffing decisions until enrollment is complete

Explanation

Cross-training and flexible resourcing allow capacity to scale with actual workload and reduce idle or overloaded periods. This balances cost against responsiveness as enrollment fluctuates.

Question 7Clinical Trial Leadership and Team Management

Which behavior most clearly demonstrates active listening by a study lead during a team meeting?

  1. Recording the speaker's words verbatim without response
  2. Preparing a rebuttal while the speaker is still talking
  3. Changing the subject to keep the meeting on schedule
  4. Summarizing the speaker's point and asking a clarifying question Correct answer.

Explanation

Active listening involves reflecting back what was heard and seeking clarification to confirm understanding. This signals engagement and reduces miscommunication.

Question 8Clinical Trial Leadership and Team Management

What is the primary purpose of a kickoff meeting at the start of a clinical trial?

  1. To conduct the first interim data analysis
  2. To align the team on objectives, roles, timelines, and expectations Correct answer.
  3. To finalize the statistical analysis plan
  4. To obtain regulatory approval for the study

Explanation

A kickoff meeting aligns team members on shared goals, responsibilities, schedules, and working expectations before execution begins. It builds shared understanding and surfaces early risks.

Question 9Clinical Trial Leadership and Team Management

A sponsor's trial team is distributed across three time zones. Which practice best supports effective collaboration while respecting work-life balance?

  1. Scheduling all meetings at the convenience of headquarters staff
  2. Rotating meeting times and documenting decisions for asynchronous review Correct answer.
  3. Relying on informal chat messages for all decisions
  4. Requiring real-time attendance at every meeting regardless of hour

Explanation

Rotating meeting times distributes inconvenience fairly, and documenting decisions enables asynchronous participation across time zones. This balances collaboration with sustainable working conditions.

Question 10Clinical Trial Leadership and Team Management

A team member raises a concern that a proposed timeline is unrealistic. As the study lead, which response best reflects constructive conflict management?

  1. Postpone all discussion until the timeline is due
  2. Dismiss the concern to preserve team morale
  3. Explore the concern with the team and adjust the plan based on evidence Correct answer.
  4. Escalate the member to human resources for insubordination

Explanation

Constructive conflict management treats disagreement as useful information and resolves it through evidence-based discussion. This improves plan quality and maintains trust.

Question 11Clinical Trial Leadership and Team Management

Which metric most directly reflects a team's adherence to trial timelines?

  1. Total number of adverse events reported
  2. Average length of informed consent forms
  3. Number of protocol amendments submitted
  4. Percentage of planned milestones achieved on schedule Correct answer.

Explanation

On-time milestone achievement directly measures schedule adherence. Other metrics reflect scope changes, safety experience, or documentation rather than timeline performance.

Question 12Clinical Trial Leadership and Team Management

A lead notices that a senior team member consistently dominates discussions, discouraging junior members from contributing. Which intervention is most appropriate?

  1. Increase the meeting length to allow more speaking time
  2. Explicitly invite input from quieter members and set norms for balanced participation Correct answer.
  3. Cancel group discussions and rely on written input only
  4. Remove the senior member from the team permanently

Explanation

Setting participation norms and actively inviting quieter voices addresses the imbalance without penalizing individuals. This preserves team cohesion while improving inclusion.

Question 13Clinical Trial Leadership and Team Management

Which approach best supports knowledge continuity when a key team member leaves mid-study?

  1. Maintaining current documentation and structured handover processes Correct answer.
  2. Restarting the study to rebuild the team from scratch
  3. Relying on that member's memory until departure
  4. Reassigning the member's tasks without any transition period

Explanation

Current documentation and structured handover preserve institutional knowledge and reduce disruption. These practices transfer context to successors efficiently.

Question 14Clinical Trial Leadership and Team Management

A study lead is delegating a monitoring task to a new coordinator. Which element is most essential to include in the delegation?

  1. The expected outcome, authority, and deadlines for the task Correct answer.
  2. A promise of promotion upon completion
  3. A guarantee that no errors will occur
  4. Instructions to consult no one else about the task

Explanation

Effective delegation clarifies the desired outcome, the authority to act, and the timeline for completion. This gives the delegatee enough context to succeed while preserving accountability.

Question 15Clinical Trial Leadership and Team Management

Which practice best demonstrates a leader's commitment to psychological safety within a trial team?

  1. Discouraging questions during busy periods
  2. Responding constructively when team members report mistakes or concerns Correct answer.
  3. Rewarding only error-free performance
  4. Attributing problems to individual staff in group settings

Explanation

Psychological safety grows when mistakes and concerns are met with constructive responses rather than blame. This encourages early reporting, which is especially valuable in trial conduct.

Question 16Clinical Trial Leadership and Team Management

A clinical trial team includes members from clinical operations, data management, and biostatistics. Which structure best supports coordinated decision-making across these functions?

  1. Informal ad hoc decisions without documentation
  2. Decision-making concentrated solely in biostatistics
  3. Siloed reporting with no cross-functional meetings
  4. A cross-functional governance forum with defined decision rights Correct answer.

Explanation

A cross-functional forum with clear decision rights aligns functions and clarifies who decides what. This reduces duplication and conflicting decisions.

Question 17Clinical Trial Leadership and Team Management

Which action best reflects a leader modeling accountability during a trial?

  1. Delegating all responsibility for outcomes to the team
  2. Redirecting blame to external vendors
  3. Acknowledging the leader's own errors and outlining corrective steps Correct answer.
  4. Avoiding commitments that could be measured

Explanation

Leaders model accountability by owning their errors and describing concrete corrective actions. This sets a norm of transparency and responsibility that teams tend to follow.

Question 18Clinical Trial Leadership and Team Management

A team lead wants to improve the effectiveness of feedback given to staff. Which practice is most consistent with best practice?

  1. Combining praise and criticism into vague general statements
  2. Providing feedback only during annual reviews
  3. Offering feedback only when problems become critical
  4. Giving specific, timely feedback focused on observable behavior Correct answer.

Explanation

Effective feedback is specific, timely, and focused on observable behavior so the recipient can act on it. Frequent, behavior-focused feedback supports continuous improvement.

Question 19Clinical Trial Leadership and Team Management

During a trial, two team members disagree about the interpretation of a protocol procedure. Which approach best reflects an evidence-based resolution?

  1. Defer the decision indefinitely to avoid conflict
  2. Split the difference between the two interpretations
  3. Defer to the more senior member's opinion
  4. Review the protocol text and applicable guidance together to reach a documented conclusion Correct answer.

Explanation

Evidence-based resolution relies on the governing documents and applicable guidance rather than hierarchy or compromise. Documenting the conclusion preserves clarity and traceability.

Question 20Clinical Trial Leadership and Team Management

A trial lead is evaluating whether to add a new team member mid-study. Which consideration is most relevant to maintaining team performance?

  1. The number of meetings the team currently holds
  2. The new member's integration needs and effect on established workflows Correct answer.
  3. The new member's social media following
  4. The length of the study's title

Explanation

Adding a member changes team dynamics and workflows, so integration planning and its effect on established processes are central considerations. These factors influence whether performance is maintained or disrupted.

Question 21Clinical Trial Leadership and Team Management

A study lead observes that a coordinator is consistently overloaded while another team member has spare capacity. Which action best reflects effective workload balancing?

  1. Ignore the imbalance because roles are fixed
  2. Redistribute tasks based on skills and capacity while maintaining clear accountability Correct answer.
  3. Assign the spare-capacity member no additional tasks to avoid disruption
  4. Ask the overloaded coordinator to work longer hours indefinitely

Explanation

Redistributing tasks according to skills and capacity, with accountability maintained, addresses imbalance sustainably. This supports both performance and well-being.

Question 22Clinical Trial Leadership and Team Management

A cross-functional trial team faces competing priorities from different functional leaders. Which leadership approach best resolves this situation?

  1. Choosing priorities based on the loudest voice in meetings
  2. Establishing shared study-level priorities and decision criteria to guide trade-offs Correct answer.
  3. Allowing each function to pursue its own priorities independently
  4. Escalating every conflict to senior management immediately

Explanation

Shared study-level priorities and explicit decision criteria allow trade-offs to be resolved consistently. This aligns functions around common objectives rather than competing agendas.

Question 23Clinical Trial Leadership and Team Management

A team lead must decide how much decision authority to delegate to a coordinator handling site communications. Which factor is most relevant to calibrating that authority?

  1. The number of emails the coordinator sends
  2. The coordinator's personal preference alone
  3. The lead's preference to retain all decisions
  4. The coordinator's experience, the risk of the decisions, and the need for oversight Correct answer.

Explanation

Delegation of authority should be calibrated to competence, the risk and reversibility of decisions, and the appropriate level of oversight. This balances empowerment with control.

Question 24Clinical Trial Leadership and Team Management

A trial team is experiencing declining morale after a series of protocol amendments. Which leadership response best addresses the underlying issue?

  1. Announcing that no further changes will ever occur
  2. Avoiding discussion of the amendments to prevent negativity
  3. Acknowledging the strain and clarifying how the changes affect roles and priorities Correct answer.
  4. Increasing monitoring pressure on individual staff

Explanation

Acknowledging strain and clarifying the practical impact of changes helps teams regain a sense of control and direction. Transparent communication addresses the root of morale decline.

Question 25Clinical Trial Leadership and Team Management

A study lead is designing a succession plan for critical trial roles. Which approach best supports resilience?

  1. Restricting knowledge of critical tasks to a single individual
  2. Identifying backups and cross-training them before vacancies occur Correct answer.
  3. Assuming key staff will remain until study completion
  4. Documenting responsibilities only after a vacancy arises

Explanation

Proactive identification of backups and cross-training builds resilience against unexpected departures. This ensures critical tasks can continue without disruption.

Question 26Clinical Trial Leadership and Team Management

Which document formally assigns responsibility for specific trial activities to named individuals or roles across participating organizations?

  1. The delegation of authority log Correct answer.
  2. The monitoring visit report
  3. The investigator's brochure
  4. The statistical analysis plan

Explanation

A delegation of authority log records which named individuals are authorized to perform specific trial-related tasks and the date that authority was assigned. It provides an auditable link between assigned duties and the people who actually carry them out. The other documents serve different purposes in trial conduct and documentation.

Question 27Clinical Trial Leadership and Team Management

A study lead is assembling the team for a first-in-human trial. Which competency is most critical to prioritize when selecting the clinical operations lead?

  1. Skill in health economics modeling
  2. Experience managing early-phase safety and dose-escalation logistics Correct answer.
  3. Expertise in post-marketing registry databases
  4. Familiarity with large simple trial designs

Explanation

First-in-human trials emphasize intensive safety monitoring, dose escalation, and close participant oversight, so operational experience with early-phase logistics is the most directly relevant competency. The other listed competencies map to later-phase or non-operational functions. Matching team competencies to trial phase is a core staffing decision.

Question 28Clinical Trial Leadership and Team Management

A study lead wants to build a team culture in which members raise protocol deviations promptly rather than conceal them. Which leadership action most directly fosters this behavior?

  1. Publishing a ranked list of team members by number of deviations reported
  2. Limiting deviation discussions to annual performance reviews
  3. Responding to self-reported errors with blame-free review focused on system causes Correct answer.
  4. Requiring deviations to be reported only after the monitor identifies them

Explanation

Prompt reporting is encouraged when staff expect that errors will be examined for underlying system causes rather than punished. Blame-free review removes the incentive to conceal problems. Ranking or deferring discussion of deviations increases fear and delays disclosure.

Question 29Clinical Trial Leadership and Team Management

A trial lead is setting performance expectations for a newly hired clinical research coordinator. Which practice best aligns individual goals with the trial's overall objectives?

  1. Setting only broad goals such as 'do your best' to preserve flexibility
  2. Setting goals jointly that trace to specific trial milestones and quality targets Correct answer.
  3. Deferring goal setting until the first annual review cycle
  4. Assigning goals copied unchanged from the previous coordinator's appraisal

Explanation

Goals are most effective when they are developed collaboratively and explicitly linked to the trial's milestones and quality targets. This alignment lets the coordinator see how daily work contributes to study objectives. Copied, deferred, or vague goals fail to connect individual effort to trial outcomes.

Question 30Clinical Trial Leadership and Team Management

Midway through a trial, a lead must decide whether to escalate a recurring site-level data quality problem to the sponsor. Which consideration should weigh most heavily in that decision?

  1. Whether escalation might reflect poorly on the lead's own performance record
  2. Whether the site has previously received any informal verbal feedback
  3. The number of staff who would need to attend an escalation meeting
  4. The potential impact of the issue on participant safety and data integrity Correct answer.

Explanation

Escalation decisions should be driven by the risk the issue poses to participant safety and data integrity, which are the trial's paramount obligations. Personal reputation, meeting logistics, and prior informal feedback are secondary factors. A consistent risk-based threshold supports defensible, timely escalation.

Question 31Regulatory Affairs and Regulatory Compliance

Which U.S. regulation establishes the core requirements for the protection of human subjects in research conducted or supported by federal agencies?

  1. The Health Insurance Portability and Accountability Act
  2. The Common Rule (45 CFR 46 Subpart A) Correct answer.
  3. The Federal Food, Drug, and Cosmetic Act
  4. The Sunshine Act

Explanation

The Common Rule, codified at 45 CFR 46 Subpart A, sets the baseline requirements for informed consent, IRB review, and protections for human subjects in federally funded research. The FD&C Act governs drugs and devices, HIPAA governs privacy of health information, and the Sunshine Act addresses payment transparency.

Question 32Regulatory Affairs and Regulatory Compliance

Under ICH E6 Good Clinical Practice, who is responsible for obtaining informed consent from a trial participant?

  1. The sponsor's clinical monitor
  2. The institutional review board chair
  3. The investigator or a delegated qualified designee Correct answer.
  4. The contract research organization auditor

Explanation

ICH E6 assigns the investigator responsibility for obtaining informed consent, which may be delegated only to qualified persons designated by the investigator. Monitors, IRB chairs, and auditors do not obtain participant consent.

Question 33Regulatory Affairs and Regulatory Compliance

A sponsor wants to begin a Phase 1 study of a new chemical entity in the United States. Which regulatory action must typically occur before the study may start?

  1. A completed risk evaluation and mitigation strategy
  2. A granted orphan drug designation
  3. An effective investigational new drug application Correct answer.
  4. An approved new drug application

Explanation

A Phase 1 study of an unapproved drug requires an IND that has gone into effect; the sponsor may generally proceed if FDA does not place the IND on clinical hold within 30 days. An NDA is a marketing application, orphan designation is an incentive, and REMS is a post-approval safety tool.

Question 34Regulatory Affairs and Regulatory Compliance

Which document describes the objective, design, methodology, statistical considerations, and organization of a clinical trial?

  1. The case report form
  2. The investigator's brochure
  3. The monitoring plan
  4. The clinical study protocol Correct answer.

Explanation

The protocol is the document that specifies how a trial will be conducted, including objectives, design, methods, and statistical analysis. The investigator's brochure summarizes preclinical and clinical data on the investigational product, while CRFs capture data and the monitoring plan governs oversight.

Question 35Regulatory Affairs and Regulatory Compliance

Under the Common Rule, which body is primarily responsible for reviewing and approving human-subject research at an institution?

  1. The data safety monitoring board
  2. The institutional biosafety committee
  3. The institutional review board Correct answer.
  4. The office of research integrity

Explanation

The Common Rule requires IRB review and approval before human-subject research may proceed. DSMBs monitor safety data, research integrity offices handle misconduct, and biosafety committees oversee recombinant DNA and biological hazards.

Question 36Regulatory Affairs and Regulatory Compliance

Which regulation governs the privacy and security of individually identifiable health information in the United States?

  1. ICH E2A
  2. HIPAA Privacy and Security Rules Correct answer.
  3. 21 CFR Part 11
  4. GDPR

Explanation

HIPAA's Privacy and Security Rules set national standards for protecting individually identifiable health information. 21 CFR Part 11 covers electronic records and signatures, GDPR is EU data protection law, and ICH E2A addresses clinical safety data management.

Question 37Regulatory Affairs and Regulatory Compliance

In a regulated clinical trial, what is the primary purpose of the investigator's brochure?

  1. To record each participant's study visits
  2. To document informed consent discussions
  3. To provide the investigator with preclinical and clinical information on the investigational product Correct answer.
  4. To list the sponsor's financial disclosures

Explanation

The investigator's brochure summarizes nonclinical and clinical data relevant to the investigational product so investigators can assess risk and manage participants safely. Participant visit records belong in source documents, consent is documented separately, and financial disclosures are handled in other records.

Question 38Regulatory Affairs and Regulatory Compliance

Which principle of the Belmont Report addresses fairness in the distribution of research burdens and benefits?

  1. Integrity
  2. Respect for persons
  3. Beneficence
  4. Justice Correct answer.

Explanation

The Justice principle concerns equitable selection of subjects and fair distribution of the burdens and benefits of research. Respect for persons concerns autonomy and informed consent, beneficence concerns risk-benefit balance, and integrity is not one of the three Belmont principles.

Question 39Regulatory Affairs and Regulatory Compliance

A trial site discovers that a participant signed a consent form that was missing a required description of risks. Which type of event is this most appropriately classified as?

  1. A major protocol violation affecting informed consent Correct answer.
  2. A serious adverse event
  3. A protocol deviation that does not affect subject safety
  4. An unanticipated problem that requires no reporting

Explanation

Use of an unapproved or deficient consent form is a significant noncompliance event because it undermines the participant's ability to give valid informed consent. It is not an adverse event, and deficiencies in consent generally require reporting to the IRB and corrective action.

Question 40Regulatory Affairs and Regulatory Compliance

Under ICH E6, which party holds ultimate responsibility for the quality and integrity of the trial data, even when activities are outsourced?

  1. The site investigator
  2. The institutional review board
  3. The contract research organization
  4. The sponsor Correct answer.

Explanation

The sponsor retains overall responsibility for trial conduct and data quality, including oversight of any transferred duties to contractors. Investigators are responsible for conduct at their sites, CROs act under agreement, and IRBs provide ethical oversight.

Question 41Regulatory Affairs and Regulatory Compliance

A sponsor plans to transfer certain trial management duties to a contract research organization. What must the sponsor do under ICH E6?

  1. Document the transfer in a written agreement and retain oversight responsibility Correct answer.
  2. Notify the FDA before the transfer
  3. Obtain participant consent for the delegation
  4. Delegate all regulatory reporting obligations to the CRO

Explanation

ICH E6 requires that any transfer of sponsor duties to a CRO be described in a written contract, with the sponsor remaining responsible for oversight and ultimate compliance. Routine FDA notification of the transfer is not required, and regulatory obligations cannot be fully shifted away.

Question 42Regulatory Affairs and Regulatory Compliance

A participant experiences a serious adverse event that is both unexpected and suspected to be caused by the investigational drug. What is the correct classification for expedited reporting?

  1. Suspected unexpected serious adverse reaction Correct answer.
  2. Protocol deviation
  3. Unanticipated problem unrelated to the study
  4. Serious adverse event requiring no reporting

Explanation

A serious, unexpected event with a reasonable possibility of causal relationship to the investigational product is a suspected unexpected serious adverse reaction (SUSAR), which triggers expedited reporting to regulators and ethics committees. Events that are expected or not suspected of being related follow routine reporting.

Question 43Regulatory Affairs and Regulatory Compliance

Which of the following best describes the purpose of 21 CFR Part 11?

  1. It establishes requirements for informed consent documentation
  2. It sets criteria for electronic records and electronic signatures to be considered trustworthy and reliable Correct answer.
  3. It defines the format for submitting marketing applications
  4. It governs the conduct of animal studies

Explanation

21 CFR Part 11 establishes the criteria under which electronic records and electronic signatures are deemed equivalent to paper records and handwritten signatures. It does not address animal studies, consent content, or application formatting.

Question 44Regulatory Affairs and Regulatory Compliance

A monitor finds that a site enrolled a participant who did not meet an inclusion criterion but was allowed to continue in the study. What is the most appropriate first action?

  1. Document the deviation, assess participant safety, and report per the protocol and IRB requirements Correct answer.
  2. Immediately withdraw the participant without further assessment
  3. Retroactively amend the inclusion criteria to match the participant
  4. Destroy the participant's data to preserve data integrity

Explanation

Deviations must be documented, their impact on participant safety and data integrity assessed, and reported according to the protocol and IRB requirements. Immediate withdrawal without assessment or destruction of data would be inappropriate, and criteria cannot be retroactively changed to mask the deviation.

Question 45Regulatory Affairs and Regulatory Compliance

Under GDPR, which legal basis is often relied upon for processing personal data in a clinical trial where consent is not the chosen basis?

  1. Vital interests of the data subject
  2. Freedom of expression
  3. Legitimate interests of the contract research organization
  4. Performance of a task carried out in the public interest or in the exercise of official authority Correct answer.

Explanation

GDPR permits processing for scientific research on several legal bases, including public interest or official authority tasks, often combined with appropriate safeguards for research. Vital interests apply only in life-or-death situations, and CRO commercial interests are rarely a valid basis for trial data.

Question 46Regulatory Affairs and Regulatory Compliance

Which entity is responsible for approving a clinical trial application in the European Union before the trial can begin in a member state?

  1. The sponsor's institutional review board in the United States
  2. The European Medicines Agency
  3. The national competent authority and ethics committee Correct answer.
  4. The World Health Organization

Explanation

In the EU, clinical trial authorization is granted by the national competent authority of the member state, working alongside an ethics committee under the Clinical Trials Regulation. EMA provides scientific evaluation and coordination but does not itself authorize individual trials.

Question 47Regulatory Affairs and Regulatory Compliance

A sponsor is preparing an annual report to regulatory authorities. Which content is typically required under ICH E2F for a development safety update report?

  1. An analysis of the safety experience during the reporting period Correct answer.
  2. Marketing and advertising materials
  3. A full copy of every case report form
  4. Individual participant financial disclosures

Explanation

The development safety update report summarizes and analyzes the safety experience of an investigational drug during the reporting interval. It does not include full CRFs, marketing materials, or financial disclosures.

Question 48Regulatory Affairs and Regulatory Compliance

Which of the following situations would most likely require reporting to the IRB as an unanticipated problem involving risk to subjects?

  1. A minor administrative delay in filing a case report form
  2. A scheduled protocol-mandated blood draw performed without complication
  3. A routine site initiation visit
  4. A breach of participant confidentiality discovered during monitoring Correct answer.

Explanation

An unanticipated problem involving risk to subjects is unexpected, related to the research, and suggests increased risk; a confidentiality breach fits this category and generally must be reported. Routine procedures, administrative delays, and monitoring visits do not meet the definition.

Question 49Regulatory Affairs and Regulatory Compliance

Which requirement applies to obtaining informed consent from a participant with limited ability to understand the information presented?

  1. The investigator may sign on behalf of the participant without documentation
  2. Consent may be obtained from any available bystander
  3. A legally authorized representative may provide consent where permitted, with assent obtained when feasible Correct answer.
  4. Consent may be waived entirely because the participant cannot read

Explanation

When a participant lacks capacity, regulations allow consent by a legally authorized representative where permitted, and assent should be sought when the participant is capable of providing it. Investigators cannot simply sign for participants, and incapacity alone does not justify waiving consent.

Question 50Regulatory Affairs and Regulatory Compliance

A sponsor wants to submit an electronic record to FDA as part of a marketing application. Which condition must be met for the record to be acceptable under 21 CFR Part 11?

  1. The record must be signed by every site investigator
  2. The record must be printed and notarized
  3. The record must be created and maintained with validated systems and appropriate controls such as audit trails Correct answer.
  4. The record must be stored only on local servers

Explanation

Part 11 requires that electronic records be generated and maintained using validated systems with controls such as audit trails, access restrictions, and secure electronic signatures. Printing and notarizing, restricting storage location, or obtaining signatures from all investigators are not Part 11 conditions.